1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street
Summary
For a while, it seemed that nothing could go wrong for Eli Lilly (LLY 0.23%). Surging sales for Lilly's type 2 diabetes ...
For a while, it seemed that nothing could go wrong for Eli Lilly (LLY 0.23%). Surging sales for Lilly's type 2 diabetes drug Mounjaro and great expectations for its obesity drug Zepbound fueled massive gains for the pharma stock.
Related Articles
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
LLY
Positive3 Dividend Growth Stocks You Can Buy and Forget About
LLY
PositiveLilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy
LLY
Neutral